DrugActi

on:Pharmaceuti
c,
Pharmacoki
neti
c,and
PharmacodynamicPhases
27.Whi chfact
or(s)mostcommonly
22.Whichdrugf
ormismostrapidl
y
affect
(s)adrug’sabsor
pti
on?(
Selectal
l
absor
bedfrom t
hegast
roi
ntest
inal(
GI)
thatapply.
)
tr
act?
a.Bodymassi
ndex
a.Capsul
e
b.Hy
pot
ensi
on
b.Subl
i
ngual
c.Pai
n
c.Suspensi
on
d.Sl
eepe
d.Tabl
et
e.
Str
ess
23.Wheredoesdisi
ntegr
ati
onofent
eri
c-
coat
edtabl
etsoccur? 28.Thepat i
enti
st akingdi
azepam
(Vali
um)foranxiety.Twodayslatershe
a.Col
onb.Li
ver
i
sst ar
tedondicl
oxaci ll
i
nforaninfect
ion.
c.Smal
li
ntest
ine Whatdoest henur seknowwi l
lhappen
tothediazepam inthepati
ent’
sbody ?
d.St
omach
a.Thedi
azepam r
emai
nshi
ghl
ypr
otei
n
24.Usuall
yfoodhaswhatef
fecton bound.
di
ssolut
ionandabsor
pti
onof
medicat
ion? b.Thedi
azepam i
sdeact
ivat
ed.

a.Accel
erat
es c.Mostoft
hedi
azepam i
srel
eased,
and
i
tbe-comesmor
eactiv
e.
b.Decel
erat
es
d.Thediazepam i
sexcr
etedi
ntheur
ine
c.Hasnoef
fect unchanged.

d.Pr
event
s 29.Whi
chbodyorgani
sthemaj
orsi
te
ofdr
ugmetabol
i
sm?
25.Whi chstat
ementplacesthefour
processesofphar-macokinet
icsi
nthe a.Ki
dney
correctsequence?
b.Li
ver
a.Absor
pti
on,
met
abol
i
sm,
dist
ri
but
ion,
excr
eti
on c.Lung

b.Di
str
ibut
ion,
absor
pti
on,
met
abol
i
sm, d.Ski
n
excr
eti
on
30.Whatrouteofdrugabsorpt
ionhas
c.Di
str
ibut
ion,
met
abol
i
sm,
absor
pti
on, thegr
eatestbioav
ail
abi
li
ty?
excr
eti
on
a.I
ntr
amuscul
ar
d.Absor
pti
on,
dist
ri
but
ion,
met
abol
i
sm,
b.I
ntr
avenous
excr
eti
on
c.Or
al
26.Whicht
ypeofdr
ugpassesr
api
dly
thr
oughtheGImembrane? d.Subcut
aneous

a.Li
pid-
sol
ubl
eandi
oni
zed 31.Whichist
hebestdescr
ipt
ionofa
drug’
sserum hal
f-
li
fe?
b.Li
pid-
sol
ubl
eandnoni
oni
zed
a.Theti
merequi
redf
orhal
fofadr
ug
c.Wat
er-
sol
ubl
eandi
oni
zed
dosetobeabsor
bed
d.Wat
er-
sol
ubl
eandnoni
oni
zed
b.Thet
imer
equi
redaf
terabsor
pti
onf
or
hal
foft
hedr
ugt
obeel
i
minat
ed 36.Whicht
ypeofdrugprev
ent
sor
i
nhibi
tsacel
lul
arr
esponse?
c.Theti
merequir
edf
oradr
ugt
obe
tot
all
yeff
ect
ive a.Agoni
st

d.Theti
merequi
redf
orhal
fofthedr
ug b.Ant
agoni
st
dosetobecompl
etel
ydi
str
ibut
ed
c.Chol
i
ner
gics
32.Thepat ientistaki
ngadr ugthathas
ahal f
-l
ifeof24t o30hour s.I
nprepari
ng d.Nonspeci
aldr
ug
dischargeteaching,whatisthedosing 37.Ar ecept
orlocatedindif
fer
entpart
s
schedulethenur seantici
pateswil
lbe ofthebody mayinit
iateavari
etyof
prescri
bedf orthismedicati
on? responsesdependingont heanatomic
a.Dai
l
y sit
e.Whi chty
peofr ecept
orrespondsin
thi
smanner ?
b.Ev
eryot
herday
a.Li
gand-
gat
ed
c.Twi
ceperday
b.Nonsel
ect
ive
d.Thr
eet
imesperday
c.Nonspeci
fi
c
33.Whicht
ypeofdr
ugcanbe
el
iminat
edthr
ought
hekidney
s? d.Pl
acebo

a.Ent
eri
c-coat
ed 38.Whi
chindicat
ormeasur
est
he
margi
nofsafetyofadr
ug?
b.Li
pid-
sol
ubl
e
a.Ther
apeut
icr
ange
c.Pr
otei
n-bound
b.Ther
apeut
ici
ndex
d.Wat
er-
sol
ubl
e
c.Dur
ati
onofact
ion
34.Theol deradultpati
enthasa
creati
nineclearanceof30mL/ min.He d.Bi
ologi
chal
f-
li
fe
hasbeenpr escr i
bedtri
met hopri
m 39.Thenur sehasjustgiv
enthepati
ent
(Prol
opr i
m)f oraurinar
yt r
actinf
ecti
on. herprescri
bedantibi
oti
c.Which
Ifthenormal doseis200mgperday , measurementchecksf orthehi
ghest
whatdoest henur seantici
patewill pl
asma/ serum concentr
ati
onofthedrug?
occurwi t
ht hedosingregimen?
a.Peakl
evel
a.Thedosewi
l
ldoubl
e.
b.Mi
nimal
eff
ect
iveconcent
rat
ion
b.Thedosewi
l
ldecr
easebyone-
hal
f.
c.Hal
f-
li
fe
c.Thedosewi
l
lst
ayt
hesame.
d.Tr
oughl
evel
d.Thedosewi
l
lincr
easet
othr
eet
imes
perday
. 40.Beforeadmi ni
steringamedication,
thenursechecksadr ugrefer
encebook
35.Whichi
sthebestdeter
minantoft
he orpamphl ettoobtainperti
nentdata.
bi
ologi
cacti
vi
tyofadrug? Whichdat ashouldthenur senote?
a.Thef
itoft
hedr
ugatt
her
ecept
orsi
te (Sel
ectallthatapply.
)

b.Themost
toft
hedr
ugatt
her
ecept
or a.Cont
rai
ndi
cat
ions
si
te b.Hal
f-
li
fe
c.I
nabil
i
tyofthedr
ugt
obi
ndt
oa c.Maxi
mum ef
fect
iveconcent
rat
ion
speci
alrecept
or
d.Pr
otei
n-bi
ndi
ngef
fect
d.Abi
li
tyoft
hedr
ugt
ober
api
dly
excr
eted e.Ther
apeut
icr
ange
41.Whichtypeofphysi
ologi
cef
fectis
notrel
atedtothedesi
redeff
ect
(s)and
arepredi
ctabl
eorassoci
atedwi
ththe
useofaspecialdr
ug?

a.Sev
ereadv
erser
eact
ions

b.Si
deef
fect
s

c.Sy
ner
gist
icef
fect
s

d.Toxi
cef
fect
s

42.Thenur sei sgivi

ngalargeinit
ial
doseofadr ugt orapi
dlyachieve
mi nimum effecti
veconcentrati
oninthe
plasma.Whati sthist
ypeofdosage
called?

a.Ther
apeut
icdose

b.Toxi
cdose

c.Loadi
ngdose

d.Peakdose

43.At i
me-r
esponsecur v
eev al
uates
parameter
sofadr ug’sacti
on.Which
parameter
(s)is/
arepar toftheti
me-
responsecurv
e?( Selectall
thatappl
y.)

a.Dur
ati
onofact
ion

b.Onsetofact
ion

c.Peakact
ion

d.Ther
apeut
icr
ange

e.Mi
nimum ef
fect
iveconcent
rat
ion

44.Whichi
ntervent
ion(s)r
egardi
ngdrug
ther
apyshouldthenurseimplement
?
(Sel
ectal
lthatappl
y.)

a.Assessforsi
deef
fects,
wit
haf
ocus
onundesir
ablesi
deeff
ects

b.Checkr
efer
encebooksordrugi
nser
ts
befor
eadmini
ster
ingt
hemedicati
on

c.Teachthepati
enttowai
toneweek
aft
erappearanceofsi
deef
fect
stosee
i
ftheydisappear

d.Checkthepatient
’sser
um t
her
apeut
ic
rangeofdrugsthathaveanar
row
therapeut
icr
ange

e.Eval
uat
epeakandtr
oughl
evel
spr
ior
toadmini
ster
ingt
hemedi
cat
ion